Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;15(8):1577-1578.
doi: 10.1007/s11739-020-02345-9. Epub 2020 Apr 29.

Camostat mesilate therapy for COVID-19

Yoshiharu Uno  1
Affiliations

Camostat mesilate therapy for COVID-19

Yoshiharu Uno. Intern Emerg Med. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Rabaan AA. Middle East respiratory syndrome coronavirus: five years later. Expert Rev Respir Med. 2017;11:901–912. doi: 10.1080/17476348.2017.1367288. - DOI - PubMed
    1. Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76–84. doi: 10.1016/j.antiviral.2015.01.011. - DOI - PMC - PubMed
    1. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:1–10. doi: 10.1016/j.cell.2020.02.052. - DOI - PMC - PubMed
    1. Sato T, Uchino J, Matsuno S, et al. A dose-finding study of FOY-305 in postoperative reflux esophagitis: a double-blind comparative study. J Clin Therap Med. 1992;8:1877–1891.
    1. Ota S, Hara Y, Kanoh S, et al. Acute eosinophilic pneumonia caused by camostat mesilate: the first case report. Respir Med Case Rep. 2016;19:21–23. - PMC - PubMed